Regencell Financial Statements From 2010 to 2024

RGC Stock  USD 3.47  0.02  0.58%   
Regencell Bioscience financial statements provide useful quarterly and yearly information to potential Regencell Bioscience Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Regencell Bioscience financial statements helps investors assess Regencell Bioscience's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Regencell Bioscience's valuation are summarized below:
Market Capitalization
44.9 M
Earnings Share
(0.45)
We have found one hundred twenty available trending fundamental ratios for Regencell Bioscience, which can be analyzed and compared to other ratios and to its competitors. Investors should ensure to check out all of Regencell Bioscience's recent performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road.
Check Regencell Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regencell main balance sheet or income statement drivers, such as Depreciation And Amortization of 658.1 K, Interest Expense of 19.8 K or Selling General Administrative of 3.8 M, as well as many exotic indicators such as Short Term Coverage Ratios of 16.18, Price Earnings Ratio of 15.35 or Price To Sales Ratio of 0.36. Regencell financial statements analysis is a perfect complement when working with Regencell Bioscience Valuation or Volatility modules.
  
This module can also supplement various Regencell Bioscience Technical models . Check out the analysis of Regencell Bioscience Correlation against competitors.

Regencell Bioscience Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets10.8 M11.4 M1.4 B
Slightly volatile
Short and Long Term Debt Total396.4 K417.3 K1.1 B
Slightly volatile
Other Current Liabilities144.2 K151.8 K59.7 M
Slightly volatile
Total Current Liabilities518.9 K546.2 K247.3 M
Slightly volatile
Property Plant And Equipment Net762.6 K802.7 K807.1 M
Slightly volatile
Current Deferred Revenue224.8 M214.1 M167.9 M
Slightly volatile
Accounts Payable200 M267 M207.1 M
Slightly volatile
Cash1.3 M1.4 M118.2 M
Slightly volatile
Cash And Short Term Investments9.9 M10.4 M121.4 M
Slightly volatile
Good Will266.7 M397.7 M314 M
Slightly volatile
Common Stock Shares Outstanding11.1 M11.7 M88.4 M
Slightly volatile
Liabilities And Stockholders Equity10.8 M11.4 M1.4 B
Slightly volatile
Non Current Liabilities Total27.8 K29.2 K1.3 B
Slightly volatile
Other Current Assets48.3 K50.9 K31.1 M
Slightly volatile
Total Liabilities540.6 K569.1 K1.6 B
Slightly volatile
Total Current Assets9.9 M10.5 M217 M
Slightly volatile
Short Term Debt374.7 K394.4 K15.7 M
Slightly volatile
Intangible Assets38.4 M50.1 M41.4 M
Slightly volatile
Net Receivables48.3 K50.9 K69.9 M
Slightly volatile
Common Stock11111753.4 K
Slightly volatile
Common Stock Total Equity85.590.053.4 K
Slightly volatile
Property Plant And Equipment Gross1.2 M1.2 M750 M
Slightly volatile
Short and Long Term Debt3.2 M4.2 M2.7 M
Slightly volatile
Capital Stock123150109
Slightly volatile
Property Plant Equipment1.8 M1.7 M501.8 K
Slightly volatile
Deferred Long Term Liabilities137.9 K155.1 K168.9 K
Slightly volatile

Regencell Bioscience Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization658.1 K692.7 K109.6 M
Slightly volatile
Selling General Administrative3.8 MM97.7 M
Slightly volatile
Other Operating Expenses5.4 M5.6 M1.4 B
Slightly volatile
Cost Of Revenue840.9 K885.1 K204.2 M
Pretty Stable
Total Operating Expenses5.4 M5.6 M723.3 M
Slightly volatile
Selling And Marketing Expenses317.2 K302.1 K70.4 K
Slightly volatile
Research Development1.1 M1.8 M661.6 K
Slightly volatile

Regencell Bioscience Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow5.5 M5.8 M103.1 M
Slightly volatile
Depreciation658.1 K692.7 K109.6 M
Slightly volatile
Dividends Paid191.8 M125 M152.8 M
Very volatile
End Period Cash Flow1.3 M1.4 M118.2 M
Slightly volatile
Change To Netincome2.2 M2.3 M2.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.360.470.5165
Slightly volatile
Dividend Yield0.09240.09730.1427
Slightly volatile
Days Of Payables Outstanding556792571
Pretty Stable
Dividend Payout Ratio2.01.421.8699
Slightly volatile
Pretax Profit Margin0.09060.07780.0737
Very volatile
Ebt Per Ebit0.610.78730.7851
Slightly volatile
Payables Turnover0.450.481.2544
Pretty Stable
Operating Profit Margin0.120.09880.1008
Slightly volatile
Effective Tax Rate0.360.4750.2811
Slightly volatile
Long Term Debt To Capitalization1.661.57690.9941
Pretty Stable
Cash Per Share1.391.46351.0338
Pretty Stable
Payout Ratio2.01.421.8699
Slightly volatile
Ebit Per Revenue0.120.09880.1008
Slightly volatile
Quick Ratio0.70.73533.5643
Slightly volatile
Net Income Per E B T0.540.5250.7099
Slightly volatile
Cash Ratio0.390.40761.1971
Slightly volatile
Operating Cash Flow Sales Ratio0.150.12960.1335
Very volatile
Days Of Sales Outstanding12.6119.1118.4714
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.580.38910.7192
Slightly volatile
Current Ratio0.780.82533.7162
Slightly volatile
Fixed Asset Turnover1.261.881.972
Very volatile
Debt Ratio1.360.83222.2514
Pretty Stable
Price Sales Ratio0.360.470.5165
Slightly volatile
Receivables Turnover27.6319.7720.1913
Pretty Stable
Asset Turnover0.881.01.1113
Slightly volatile
Net Profit Margin0.05460.04080.0418
Pretty Stable
Gross Profit Margin0.981.110.9268
Pretty Stable
Operating Cycle84.2880.2767.0784
Slightly volatile

Regencell Fundamental Market Drivers

Cash And Short Term Investments11.6 M

Regencell Upcoming Events

26th of January 2024
Upcoming Quarterly Report
View
30th of September 2023
Next Fiscal Quarter End
View

About Regencell Bioscience Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Regencell Bioscience income statement, its balance sheet, and the statement of cash flows. Regencell Bioscience investors use historical funamental indicators, such as Regencell Bioscience's revenue or net income, to determine how well the company is positioned to perform in the future. Although Regencell Bioscience investors may use each financial statement separately, they are all related. The changes in Regencell Bioscience's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Regencell Bioscience's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Regencell Bioscience Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Regencell Bioscience. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Current Deferred Revenue214.1 M224.8 M
Total Revenue 0.00  0.00 
Cost Of Revenue885.1 K840.9 K
Ebit Per Revenue 0.1  0.12 

Currently Active Assets on Macroaxis

When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:
Check out the analysis of Regencell Bioscience Correlation against competitors.
Note that the Regencell Bioscience information on this page should be used as a complementary analysis to other Regencell Bioscience's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Regencell Stock analysis

When running Regencell Bioscience's price analysis, check to measure Regencell Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regencell Bioscience is operating at the current time. Most of Regencell Bioscience's value examination focuses on studying past and present price action to predict the probability of Regencell Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regencell Bioscience's price. Additionally, you may evaluate how the addition of Regencell Bioscience to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Is Regencell Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.45)
Return On Assets
(0.26)
Return On Equity
(0.42)
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.